| Minor Use Minor Species Development of Drugs (R01) | Food and Drug Administration | $250,000 | Jan 29, 2027 |
| Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed | Food and Drug Administration | $300,000 | Apr 1, 2027 |
| NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens | Food and Drug Administration | $200,000 | Apr 1, 2027 |
| Laboratory Flexible Funding Model (LFFM) | Food and Drug Administration | $1,500,000 | Jan 11, 2028 |
| Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) | Food and Drug Administration | $600,000 | Feb 8, 2028 |
| Animal and Veterinary Innovation Centers (U18) | Food and Drug Administration | $1,250,000 | May 12, 2028 |
| Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required) | Food and Drug Administration | $900,000 | May 16, 2028 |
| Vet-LIRN Capacity-Building Project and Equipment Grants (U18) | Food and Drug Administration | $2,500,000 | Sep 4, 2028 |
| Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required) | Food and Drug Administration | Not specified | Forecast |
| Conformance with the Egg Regulatory Program Standards | Food and Drug Administration | $47,000 | Forecast |
| Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) | Food and Drug Administration | $400,000 | Forecast |
| Food Safety Capacity and Infrastructure Building (U2F) | Food and Drug Administration | $1,000,000 | Forecast |
| FDA's Integrated Food Safety System Training Delivery and Development | Food and Drug Administration | Not specified | Forecast |
| Federal and State Integration Activities to Advance Cooperation and Regulatory Standards Among Animal Food Safety Regulatory Programs | Food and Drug Administration | Not specified | Forecast |
| Reducing Fraud and Lowering Barriers to the Production of Drugs in Shortage by Outsourcing Facilities | Food and Drug Administration | $3,000,000 | Forecast |
| Data Standards for Tobacco Research and Scientific Review Phase 2 | Food and Drug Administration | Not specified | Forecast |
| FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed) | Food and Drug Administration | Not specified | Forecast |
| Center for Research on Complex Generics (U18) Clinical Trials Optional | Food and Drug Administration | $1,500,000 | Forecast |
| NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens | Food and Drug Administration | $4,500,000 | Forecast |
| REACHing Communities (REACH) Consortium (U01) Clinical Trials Optional | Food and Drug Administration | $3,000,000 | Forecast |
| Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed | Food and Drug Administration | $300,000 | Forecast |
| FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed | Food and Drug Administration | $1,000,000 | Forecast |
| Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional | Food and Drug Administration | $500,000 | Forecast |
| Minor Use Minor Species Development of Drugs (R01) | Food and Drug Administration | $250,000 | Forecast |
| Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required) | Food and Drug Administration | $250,000 | Forecast |
| Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) Clinical Trial Not Allowed | Food and Drug Administration | $200,000 | Forecast |
| Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics | Food and Drug Administration | Not specified | Forecast |
| Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed | Food and Drug Administration | $250,000 | Forecast |
| OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed | Food and Drug Administration | $250,000 | Forecast |
| Manufactured Foods Flexible Funding Model (MF-FFM) | Food and Drug Administration | Not specified | Forecast |
| Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01) | Food and Drug Administration | $350,000 | Forecast |
| Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed | Food and Drug Administration | Not specified | Forecast |
| Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed | Food and Drug Administration | $2,000,000 | Forecast |
| Retail Food Safety Regulatory Association Collaboration CAP | Food and Drug Administration | $4,000,000 | Forecast |
| Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required | Food and Drug Administration | $900,000 | Forecast |
| Development and Maintenance of Human and Animal Food Rapid Response Teams (U2F) Clinical Trials Not Allowed | Food and Drug Administration | $1,440,000 | Forecast |
| Cooperative Agreement to Support a Human Abuse Potential Study of Botanical Kratom (U01 Clinical Trial Required) | Food and Drug Administration | $2,000,000 | Forecast |
| Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives | Food and Drug Administration | $10,600,000 | Forecast |
| Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional | Food and Drug Administration | $300,000 | Forecast |
| Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed | Food and Drug Administration | $300,000 | Forecast |
| FDA OMHHE Convener for Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH) | Food and Drug Administration | Not specified | Forecast |
| Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed | Food and Drug Administration | $1,000,000 | Forecast |
| Animal Food Regulatory Program Alliance | Food and Drug Administration | $600,000 | Forecast |
| Studies Addressing Rare Neurodegenerative Diseases including ALS | Food and Drug Administration | Not specified | Forecast |
| Identification of Drug-related and Formulation-Related Factors that Result in Alcohol Dose Dumping of Modified Release Oral Drug Products (U01) Clinical Trial Not Allowed | Food and Drug Administration | $250,000 | Forecast |
| Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines | Food and Drug Administration | $1,000,000 | Forecast |
| Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed | Food and Drug Administration | $1,285,000 | Forecast |
| Integrated Food Safety System Regulatory and Laboratory Training System National Coordination Center | Food and Drug Administration | $1,500,000 | Forecast |
| African Medical Devices Regulatory Harmonization Program | Food and Drug Administration | Not specified | Forecast |
| Collaborations to Enhance Drug Development and Regulatory Science | Food and Drug Administration | $5,000,000 | Forecast |
| Rapid Response Team (RRT) Cooperative Agreement | Food and Drug Administration | Not specified | Forecast |
| Critical Path Public Private Partnerships Clinical Trials Optional | Food and Drug Administration | $20,000,000 | Forecast |
| Retail Food Safety Regulatory Association Collaboration | Food and Drug Administration | Not specified | Forecast |
| Novel approaches to support therapeutic development in ultra-rare cancers | Food and Drug Administration | Not specified | Forecast |